Patents Assigned to ONCOC4, INC.
  • Anti-CD24 compositions and uses thereof
    Patent number: 12286485
    Abstract: Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 29, 2025
    Assignees: OncoC4, Inc., Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Rhonda Flores, Hung-Yen Chou, Zhihong Xue, Peiying Ye, Martin Devenport
  • CD80 and CD86 binding protein compositions and uses thereof
    Patent number: 12227557
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: February 18, 2025
    Assignees: OncoC4, Inc., Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Wei Wu, Xuexiang Du, Mingyue Liu, Fei Tang
  • Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
    Patent number: 12129299
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 29, 2024
    Assignees: OncoC4, Inc., University of Maryland, Baltimore
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • ANTI-SIGLEC COMPOSITIONS AND USES THEREOF
    Publication number: 20240218067
    Abstract: The disclosure relates to anti-Siglec-10 antibodies and the use of such antibodies in cancer therapy.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 4, 2024
    Applicants: ONCOC4, INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Mingyue LIU
  • Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
    Patent number: 11629188
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: April 18, 2023
    Assignee: ONCOC4, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20220259286
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 18, 2022
    Applicants: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20220259285
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 18, 2022
    Applicants: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • CD80 and CD86 binding protein compositions and uses thereof
    Patent number: 11261233
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 1, 2022
    Assignees: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Wei Wu, Xuexiang Du, Mingyue Liu, Fei Tang